EMPE Diagnostics

EMPE Diagnostics

Reliable diagnosis of multi-drug resistant tuberculosis (MDR-TB) within 2 h without requiring special infrastructure.

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR201620172018201920202021
Revenues<1m<1m<1m<1m--
% growth-(1 %)(39 %)(94 %)--
EBITDA(<1m)(<1m)(<1m)(<1m)(<1m)(<1m)
% EBITDA margin(205 %)(508 %)(2234 %)(82851 %)--
Profit(<1m)(<1m)(<1m)(<1m)(<1m)(<1m)
% profit margin(234 %)(640 %)(2708 %)(93548 %)--

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound
-

N/A

-
N/A

SEK9.7m

Early VC

€50.0k

Grant

SEK23.8m

Series A

€2.5m

Grant
Total FundingAUD10.6m

Recent News about EMPE Diagnostics

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.